AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-699-7855
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees12
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable
AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions
What is AzurRx BioPharma's stock symbol?
AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."
When is AzurRx BioPharma's next earnings date?
What price target have analysts set for AZRX?
6 brokerages have issued 12 month target prices for AzurRx BioPharma's shares. Their predictions range from $5.00 to $10.50. On average, they expect AzurRx BioPharma's share price to reach $7.4167 in the next year. This suggests a possible upside of 544.9% from the stock's current price. View Analyst Price Targets for AzurRx BioPharma.
What is the consensus analysts' recommendation for AzurRx BioPharma?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AzurRx BioPharma.
What are Wall Street analysts saying about AzurRx BioPharma stock?
Here are some recent quotes from research analysts about AzurRx BioPharma stock:
- 1. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $199M, which includes a discounted cash flow- based asset value of $201M for MS1819, using a 15% discount rate and 2% terminal growth rate, excluding $2M convertible debt, with 50% probability of success. Risks include, but are not limited to: (1) failure of MS1819 in clinical trials; (2) failure of MS1819 to secure regulatory approval; (3) failure of MS1819 to achieve commercial success due to reimbursement, penetration rate, and/or competition; and (4) dilution risk." (8/14/2019)
- 2. Maxim Group analysts commented, "AzurRx announced that its Phase 2 OPTION trial of MS1819-SD for EPI in cystic fibrosis (CF) is now over 50% enrolled. The timeline for data remains on track for mid-2019, with read out expected in the summer. Unlike current standard of care porcine-derived pancreatic enzymes (PPEs), MS1819-SD is a yeast-derived recombinant lipase which has shown a favorable safety profile so far. It may be able to reduce pill burden and improve QoL in CF patients with exocrine pancreatic insufficiency (EPI). Conclusion. We view the news as a positive for the company as the Phase 2 OPTION data this summer represents an important catalyst for AZRX shares that can drive valuation." (4/24/2019)
Has AzurRx BioPharma been receiving favorable news coverage?
News coverage about AZRX stock has been trending positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AzurRx BioPharma earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near future. View News Stories for AzurRx BioPharma.
Are investors shorting AzurRx BioPharma?
AzurRx BioPharma saw a drop in short interest in the month of July. As of July 31st, there was short interest totalling 95,300 shares, a drop of 81.0% from the June 30th total of 502,100 shares. Based on an average trading volume of 209,100 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.9% of the company's stock are short sold. View AzurRx BioPharma's Current Options Chain.
Who are some of AzurRx BioPharma's key competitors?
Some companies that are related to AzurRx BioPharma include Entasis Therapeutics (ETTX), Tocagen (TOCA), Aduro BioTech (ADRO), AgeX Therapeutics (AGE), Aptinyx (APTX), Eton Pharmaceuticals (ETON), Verastem (VSTM), Correvio Pharma (CORV), Abeona Therapeutics (ABEO), Avenue Therapeutics (ATXI), Millendo Therapeutics (MLND), Savara (SVRA), Processa Pharmaceuticals (PCSA), Sunesis Pharmaceuticals (SNSS) and Aquestive Therapeutics (AQST).
What other stocks do shareholders of AzurRx BioPharma own?
Who are AzurRx BioPharma's key executives?
AzurRx BioPharma's management team includes the folowing people:
- Mr. Johan M. Spoor, Pres, CEO & Director (Age 47)
- Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA, CFO & Director (Age 55)
- Mr. Daniel Dupret, Chief Scientific Officer (Age 63)
- Dr. Mathieu Schué Ph.D., Head of Laboratory
- Dr. James E. Pennington, Chief Medical Officer (Age 76)
When did AzurRx BioPharma IPO?
(AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO.
Who are AzurRx BioPharma's major shareholders?
AzurRx BioPharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.00%), BlackRock Inc. (0.16%), JPMorgan Chase & Co. (0.13%) and Royal Bank of Canada (0.11%). Company insiders that own AzurRx BioPharma stock include Charles J Casamento, Edmund Burke Jr Ross, Johan M Spoor and Maged Shenouda. View Institutional Ownership Trends for AzurRx BioPharma.
Which institutional investors are buying AzurRx BioPharma stock?
AZRX stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., JPMorgan Chase & Co., Royal Bank of Canada and BlackRock Inc.. Company insiders that have bought AzurRx BioPharma stock in the last two years include Charles J Casamento, Edmund Burke Jr Ross, Johan M Spoor and Maged Shenouda. View Insider Buying and Selling for AzurRx BioPharma.
How do I buy shares of AzurRx BioPharma?
Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AzurRx BioPharma's stock price today?
One share of AZRX stock can currently be purchased for approximately $1.15.
How big of a company is AzurRx BioPharma?
AzurRx BioPharma has a market capitalization of $30.02 million. The company earns $-13,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. AzurRx BioPharma employs 12 workers across the globe.View Additional Information About AzurRx BioPharma.
What is AzurRx BioPharma's official website?
How can I contact AzurRx BioPharma?
AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]
MarketBeat Community Rating for AzurRx BioPharma (NASDAQ AZRX)
MarketBeat's community ratings are surveys of what our community members think about AzurRx BioPharma and other stocks. Vote "Outperform" if you believe AZRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
